Abstract

Fortrea Holdings Inc. will report its second-quarter 2026 results on July 29, 2026 Pre-MKt, with the market expecting revenue of 647.46 million US dollars and adjusted EPS of 0.18 based on recent estimates, alongside improving operating income momentum.

Market Forecast

Consensus for the current quarter points to revenue of 647.46 million US dollars, up 2.86% year over year, EBIT of 38.70 million US dollars, up 36.45% year over year, and adjusted EPS of 0.18, up 188.28% year over year; forecasts for gross profit margin and net profit margin are not available. Management reaffirmed full-year 2026 guidance in late June, and investors will look for a run-rate that supports that framework while monitoring margins and cash conversion for signs of sequential improvement. Clinical Services remains the core revenue engine and should continue to shape the quarter’s revenue and profit cadence; mix and utilization within this line will be the primary swing factors. Support Services is the smaller but potentially more accretive spending area by mix; applying recent proportions to the quarter’s revenue estimate implies roughly 56.12 million US dollars for this segment, though year-over-year detail isn’t separately disclosed.

Last Quarter Review

In the previous quarter, Fortrea Holdings Inc. delivered revenue of 636.50 million US dollars (down 2.27% year over year), a gross profit margin of 19.42%, GAAP net loss attributable to shareholders of 23.60 million US dollars, a net profit margin of -3.71%, and adjusted EPS of 0.16 (up 700% year over year). A notable highlight was operating momentum, with EBIT reaching 25.50 million US dollars, an increase of 38.59% year over year, underscoring expense discipline and early signs of margin repair. By revenue mix, Clinical Services contributed approximately 581.33 million US dollars and Support Services around 55.17 million US dollars; segment-specific year-over-year growth rates were not provided.

Current Quarter Outlook

Clinical Services: Revenue trajectory, margin mechanics, and backlog conversion

Current-quarter expectations imply that Clinical Services should represent the vast majority of revenue again, consistent with its recent mix of a little over nine-tenths of company sales. Translating that proportion onto the 647.46 million US dollars revenue estimate suggests around 591.34 million US dollars from Clinical Services, reinforcing that even modest mix or utilization shifts inside this line can meaningfully influence consolidated gross profit and EBIT. With the prior quarter’s gross profit margin at 19.42%, the debate is whether operating leverage from fuller utilization and better pass-through management can outpace wage and project start-up frictions to lift gross profitability sequentially. The path to an improving EBIT profile this quarter hinges on two operational elements within Clinical Services. First, conversion of executed awards into revenue at a pace that sustains the mid-single-digit top-line run-rate is essential to validating the revenue estimate of 647.46 million US dollars. Second, the ability to absorb project onboarding costs without repeating last year’s margin volatility will be closely watched, especially because the prior quarter showed a return to positive EBIT with 25.50 million US dollars. If project mix includes a greater share of execution-phase work relative to startup, it could support incremental gross margin improvement, which would in turn leverage into EBIT given a largely fixed support structure through the quarter. Analysts anticipating EPS of 0.18 and EBIT of 38.70 million US dollars are implicitly assuming stable or slightly improved margins in the Clinical Services core. Execution that keeps site activation and monitoring schedules on track would support this assumption, while any adverse slippage risks concentrating pressure on both gross margin and overhead absorption. The setup therefore centers less on a step-change in revenue and more on whether Clinical Services demonstrates steady throughput and cost control sufficient to translate modest revenue growth into a larger percentage increase in EBIT and EPS.

Support Services: Expansion path and profit sensitivity

Support Services is smaller by revenue weight but can disproportionately influence profit quality depending on the quarter’s fee mix and delivery efficiency. Applying the recent mix to consensus revenue implies about 56.12 million US dollars in Support Services this quarter. While year-over-year growth is not disclosed, the contribution’s importance lies in its potential to be either slightly margin-accretive or margin-dilutive depending on the proportion of higher-value consulting and technology-enabled work captured in the period. From a P&L construction standpoint, even incremental gross profit from Support Services could visibly aid EBIT flow-through given the modest size of the segment relative to consolidated revenue. This quarter’s consensus rise in EBIT of 36.45% year over year against only 2.86% revenue growth implicitly counts on some combination of improved labor utilization, better fee capture, or favorable project mix that may include Support Services. Investors should therefore pay attention to commentary about operational integration across service lines, as tighter coordination can both streamline delivery costs and reduce cycle times, enhancing contribution margins. The segment’s directional impact on sentiment will likely be binary: confirmation that Support Services is scaling efficiently could bolster confidence in the EPS estimate of 0.18, while signs of uneven delivery or heavier low-margin work would introduce risk to the anticipated margin uplift. Because the segment starts from a smaller revenue base, management commentary on attach rates, cross-sell into Clinical Services programs, and backlog visibility can provide early evidence of whether Support Services will be an upside lever or a neutral factor in the quarter.

Stock Price Drivers This Quarter: Guidance tone, margin cadence, and cash flow

With the company having reaffirmed full-year 2026 revenue and adjusted EBITDA guidance in late June, investors will be sensitive to the tone and specificity of any update. If the company reiterates that the quarter’s performance aligns with its full-year framework while highlighting cost control wins, the market may treat that as validation for the expected EBIT step-up to 38.70 million US dollars and the 0.18 adjusted EPS print. Conversely, if management signals that timing of project starts or staffing dynamics has pushed certain revenue or margin contributions into later quarters, that could color the trajectory for the second half without necessarily breaking the full-year outlook. Margin cadence is another critical driver. The last quarter’s gross profit margin of 19.42% established a starting point for the year, and the move from a GAAP net loss of 23.60 million US dollars to a materially higher adjusted EPS this quarter implies better overhead absorption and lower transient costs. A stable or improved net profit margin versus last quarter’s -3.71% would enhance confidence in margin repair, even if management refrains from offering precise quarterly margin targets. Any color on non-recurring items, separation or transformation expenses, or pricing and pass-through dynamics will help investors parse the durability of margin progress. Finally, cash conversion and working capital discipline often react faster than GAAP earnings to changes in execution quality. While no explicit cash flow targets are available for the quarter, commentary that days sales outstanding and milestone collections remain on track would reinforce the narrative that modest revenue growth can translate into outsized gains in operating income and cash generation. In aggregate, a clean delivery on the revenue estimate, corroborated by EBIT near 38.70 million US dollars and an adjusted EPS of 0.18, would likely be sufficient to support a constructive response from the market, particularly if the full-year guidance stays intact.

Analyst Opinions

Bullish views dominate among the opinions compiled during the period, with two of three explicit rating updates leaning positive. Evercore ISI, through analyst Elizabeth Anderson, maintained a Buy rating and a 25.00 US dollars price target, framing the equity story around improving earnings quality as margins normalize. Truist maintained a Buy rating and increased its price target to 19.00 US dollars, a stance that implicitly aligns with the expected step-up in profitability this quarter despite comparatively modest top-line growth. These constructive calls cohere with the current consensus pattern: year-over-year revenue growth of 2.86% coupled with a much larger year-over-year gain in EBIT of 36.45% and an 188.28% year-over-year advance in adjusted EPS. The bullish camp sees this spread between revenue growth and earnings growth as evidence that sequential operational improvements and tighter cost control are translating into more efficient earnings, with further potential as project mix and utilization stabilize. The expected EBIT of 38.70 million US dollars underscores how incremental margin gains within the core Clinical Services workflow can significantly strengthen earnings even when revenue grows in the low single digits. From a valuation and sentiment perspective, bulls argue that confirmation of this quarter’s trajectory would help narrow the gap between current trading levels and their targets by establishing a repeatable cadence of mid-single-digit revenue growth converting into healthier double-digit operating income gains. On the call, they will look for proof points such as sustained gross margin stability relative to the prior quarter’s 19.42%, guardrails around overhead growth, and any signals that Support Services can maintain or improve its margin contribution without adding execution risk. If the company reaffirms or tightens the full-year revenue and adjusted EBITDA guardrails, bulls expect the market to extrapolate greater confidence into the second half, particularly if cash conversion commentary is constructive. In practical terms, these analysts are setting a bar that is neither trivial nor dependent on aggressive top-line acceleration. Instead, it is shaped around operational consistency, careful mix management within Clinical Services, and incremental progress in Support Services. Should Fortrea Holdings Inc. meet or slightly exceed the consensus—revenue of 647.46 million US dollars, EBIT around 38.70 million US dollars, and adjusted EPS of 0.18—bullish institutions anticipate that the market will credit the company with credible margin repair and a clearer line of sight to full-year objectives. They also highlight that this combination of modest revenue growth and stronger profit progression can unlock further estimate revisions if replicated over multiple quarters, creating a reinforcing cycle for sentiment. By focusing on margin quality, maintaining discipline on overhead, and offering transparent commentary that ties the quarter’s results to the full-year construct, management can supply the elements the bullish majority is keyed to hear. These institutions view the current setup as favoring positive revision risk on profitability metrics more than on revenue, implying that execution updates on costs, utilization, and project timing may carry more weight for the share price reaction than beats or misses within a few million dollars of the revenue estimate. In sum, the bullish consensus expects the upcoming print to validate early progress toward earnings normalization, laying groundwork for steadier compounding through the second half of 2026.